This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $447,009 to the University of Massachusetts to conduct research on the early immune response to Mycobacterium tuberculosis (MTB) infection. The key objectives are to: 1) Categorize alveolar macrophage sensing abilities and defects in responding to MTB pathogen-associated molecular patterns, and screen for novel...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,413,412 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Texas Biomedical Research Institute to study mechanisms for controlling Mycobacterium tuberculosis (MTB) infection in the lungs. The project aims to understand the immune responses generated by an attenuated, live-replicating MTB strain that has demonstrated protective efficacy in non-human primate models....
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $769,925.00 to the University of Arkansas for Medical Sciences (UAMS) to conduct research on the ontogeny and metabolism of lung alveolar macrophages in tuberculosis (TB). The key objectives of this 5-year research project are to: 1) determine how the ontogeny (origin) of alveolar macrophages contributes to...
This federal Project Grant award, valued at $155,227.00 and awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to generate proof-of-concept data on a novel treatment strategy for Mycobacterium abscessus (MAB) chronic lung disease. The primary objective is to investigate whether a monoclonal antibody (CMTX-101) can effectively disrupt MAB biofilms in the lungs, which is a key factor limiting...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $240,878 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Medical University of South Carolina (MUSC). The purpose of this 1-year grant, with an award date of June 2, 2025, is to support the planning and preparatory activities required to initiate a future clinical trial investigating the efficacy and safety of the antibiotic omadacycline for treating Mycobacterium abscessus...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) totaling $831,755 supports research to investigate the role of lung-resident macrophage subsets, particularly nerve- and airway-associated macrophages (NAMs), in regulating type 2 immune responses and tissue homeostasis. The research aims to elucidate the mechanisms by which these macrophage populations mediate protective...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $895,538 to support research aimed at developing shorter and more effective oral treatment regimens for Mycobacterium abscessus pulmonary disease. The research seeks to identify optimized drug combinations, including both FDA-approved agents and novel preclinical/clinical candidates, that can rapidly reduce...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $565,149 to Health Research, Inc. Wadsworth Center Division to conduct research on RNA-based regulatory mechanisms in Mycobacterium tuberculosis (MTB). The primary objectives are to: Define the regulatory interactions of the sRNA MCR11 and its impact on gene expression in MTB. Characterize the roles of RNA-ABMR...
This $162,000 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The Washington University, the grant recipient, will leverage their mouse model of MTB infection to quantify pDC lung trafficking, identify the chemokine receptor required for pDC lung...
The federal Project Grant award R01AI175935 for $3,492,664.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define immunologic and transcriptomic signatures of Mycobacterium avium complex (MAC) pulmonary disease and microbiologic treatment response. The award funds the collection of longitudinal blood and sputum samples from patients starting treatment for MAC pulmonary disease, and the conduct of high-throughput cytometry and RNA sequencing analyses to identify immune and transcriptomic signatures associated with disease and treatment response. The project involves two sub-awards to The University of Texas Health Science Center at Tyler and the Medical University of South Carolina to support specific aspects of the research. The goal is to develop non-invasive biomarkers that can better guide diagnostic and therapeutic decision-making for MAC pulmonary disease.